Ipatasertib

TargetMol
Product Code: TAR-T6252
Supplier: TargetMol
CodeSizePrice
TAR-T6252-2mg2mg£102.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6252-1mL1 mL * 10 mM (in DMSO)£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6252-5mg5mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6252-10mg10mg£135.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6252-25mg25mg£185.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6252-50mg50mg£262.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6252-100mg100mg£367.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Ipatasertib (GDC-0068), a highly specific pan-Akt inhibitor, targets Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM, respectively.
CAS:
1001264-89-6
Formula:
C24H32ClN5O2
Molecular Weight:
458
Pathway:
Cytoskeletal Signaling; PI3K/Akt/mTOR signaling
Purity:
0.9828
SMILES:
C(=O)([C@H](CNC(C)C)c1ccc(cc1)Cl)N1CCN(CC1)c1c2c(ncn1)[C@@H](C[C@H]2C)O
Target:
Akt

References

Tabernero J, et al. Ann Oncol, 2011, 22(suppl 3), abstract IL33. Roel Funke, et al. American Society of Clinical Oncology (ASCO) Annual Meeting, 1-5, 2012. Lin K. Cancer Res, 2011, 71(8 Supplement), abstract DDT02-01. James F. Blake. 2011. Heidi M. Savage, et al. Cancer Res, 2012, 72(8 Supplement), 966.